CASK and focal segmental glomerulosclerosis: Given the secretion of circulating CASK into the sera of patients with recurrent FSGS, it holds promise as a novel biomarker or therapeutic target for recurrent FSGS, thereby conveniently reflecting renal lesions and potentially reducing the frequency of renal biopsy.